Elanco Animal Health Incorporated $ELAN Shares Sold by Hsbc Holdings PLC

Key Points

• Hsbc Holdings PLC significantly reduced its stake in Elanco Animal Health by 78.8%, now holding approximately $248,000 worth of shares after selling 87,750 shares in the first quarter.
• Various hedge funds have altered their positions in Elanco, with GAMMA Investing LLC increasing its holdings by 1,743.8%, indicating a shift in investor sentiment towards the company.
• Elanco Animal Health reported earnings of $0.26 per share for the last quarter, surpassing analyst expectations, with an increase in revenue of 4.8% compared to the previous year.

Hsbc Holdings PLC lessened its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 78.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 23,648 shares of the company's stock after selling 87,750 shares during the quarter. Hsbc Holdings PLC's holdings in Elanco Animal Health were worth $248,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the stock. Yousif Capital Management LLC purchased a new position in shares of Elanco Animal Health during the 1st quarter worth $119,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Elanco Animal Health during the 1st quarter valued at about $111,000. SG Americas Securities LLC acquired a new position in shares of Elanco Animal Health during the 1st quarter valued at about $891,000. GAMMA Investing LLC boosted its position in shares of Elanco Animal Health by 1,743.8% during the 1st quarter. GAMMA Investing LLC now owns 12,390 shares of the company's stock valued at $130,000 after acquiring an additional 11,718 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its position in shares of Elanco Animal Health by 127.5% during the 4th quarter. Ameriprise Financial Inc. now owns 97,373 shares of the company's stock valued at $1,179,000 after acquiring an additional 54,581 shares during the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Trading Up 5.3%

NYSE:ELAN traded up $0.93 on Friday, reaching $18.40. 6,921,928 shares of the company's stock were exchanged, compared to its average volume of 10,348,335. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $9.14 billion, a price-to-earnings ratio of 21.39, a price-to-earnings-growth ratio of 3.42 and a beta of 1.62. The business has a fifty day moving average of $15.95 and a 200-day moving average of $12.93. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $18.87.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The business's revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. UBS Group boosted their price target on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Stifel Nicolaus boosted their price target on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday, July 2nd. William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Wall Street Zen raised shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Finally, Leerink Partnrs raised shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 17th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $17.33.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.